Clinical Testing News and Research

RSS

FDA approves clinical testing of SanBio's SB623 for stroke recovery

SanBio Inc. announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

17 Jun 2010

When doctors don't comment, parents tend to underestimate preschool children's weight: Study

Parents are more likely to underestimate their preschool children's weight when pediatricians do not tell them their children are overweight or gaining weight too fast, a study by the University of South Florida and Johns Hopkins University reports.

16 Jun 2010

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Adeona Pharmaceuticals, Inc. announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab subsidiary.

15 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

Officials at Texas Tech University System's Office of Technology Commercialization announced Wednesday (June 9) the signing of an exclusive worldwide license agreement for a chemical additive called an aptamer that makes certain existing antibiotics viable against antibiotic-resistant bacteria.

10 Jun 2010

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

QuantRx Biomedical Corporation, a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader thyroid testing system.

9 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

Blood vessel-blocking drug slows prostate cancer progression: Experts

A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.

9 Jun 2010

Covance opens state-of-the-art biorepository facility at Greenfield

Covance Inc., a leading provider of drug development services, announced today that it has opened a state-of-the-art biorepository facility at its Greenfield, Indiana location. The 20,000-square-foot building is dedicated to long-term storage of clinical trial specimens. The facility is able to store a wide-range of specimens, including plasma, serum, whole blood, DNA, PBMC, and tissue.

9 Jun 2010

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Helix BioPharma Corp. today announced results from the Phase II clinical trial assessing the efficacy and safety of Topical Interferon Alpha-2b cream for the treatment of ano-genital warts (AGW).

9 Jun 2010

$Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010$

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.

8 Jun 2010

Rice University students develop new device to help children with acute respiratory infections

Gently, gently. That's how babies should be handled, and it was the prime consideration when a team of Rice University seniors developed a device that could save babies' lives.

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

CombinatoRx, Incorporated today announced that it has received a milestone payment from Fovea Pharmaceuticals, a division of Sanofi Aventis, relating to Fovea's initiation of Phase 2b clinical testing of PrednisporinTM (FOV1101) in subjects with persistent allergic conjunctivitis. Prednisporin™ is a CombinatoRx-derived combination drug candidate that was exclusively licensed to Fovea by CombinatoRx.

7 Jun 2010

Amorfix Life Sciences signs licensing agreement with PREVENT

Amorfix Life Sciences Ltd. and Pan-Provincial Vaccine Enterprise Inc. of Saskatoon, Saskatchewan, today announced that the two groups have entered into a licensing agreement granting PREVENT exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis vaccines.

3 Jun 2010

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, announced today that the company's highly selective oral kinase inhibitor, Telatinib, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of gastric cancer.

3 Jun 2010

Insulin pills to manage diabetes are finally moving ahead in clinical trials

After years of research and anticipation, insulin pills that could make it easier for millions of patients worldwide to manage diabetes are finally moving ahead in clinical trials and a step-closer to the medicine cabinet. That's among the topics highlighted in a two-part cover story on drug manufacturing in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

3 Jun 2010

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

A two-year, $12 million contract with the U.S. Department of Defense Office of Technology Transition (OTT) will jumpstart human trials of three innovative research programs that aim to replace scars and defects with healthy, functional tissues, announced officials of the University of Pittsburgh and the McGowan Institute for Regenerative Medicine today at the Institute's Second Annual Open Session, Soldiers and Sailors Memorial Hall, Oakland.

31 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

Covidien launches V-Loc 90 knotless wound closure device

Covidien, a leading global provider of healthcare products, today announced the global launch of the V-Loc 90 device, expanding its family of V-Loc absorbable wound closure devices. This latest addition to Covidien's knotless wound closure product line received 510(k) clearance from the U.S. Food and Drug Administration on May 11, 2010.

27 May 2010

Clinical Testing News and Research

FDA approves clinical testing of SanBio's SB623 for stroke recovery

When doctors don't comment, parents tend to underestimate preschool children's weight: Study

Adeona's HartLab expands diagnostic testing services to include full array of microbiology testing

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Texas Tech signs worldwide license agreement for metallo-beta-lactamase inhibitors with RI Scientific

QuantRx Biomedical completes clinical testing of Q-Reader thyroid testing system

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Blood vessel-blocking drug slows prostate cancer progression: Experts

Covance opens state-of-the-art biorepository facility at Greenfield

Helix BioPharma reports Phase II clinical results of Topical Interferon Alpha-2b for ano-genital warts

Progenics presents Phase 1 PSMA ADC therapy study data for taxane-refractory prostate cancer at ASCO 2010

Rice University students develop new device to help children with acute respiratory infections

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Fovea's initiation of Prednisporin Phase 2b clinical testing triggers milestone payment to CombinatoRx

Amorfix Life Sciences signs licensing agreement with PREVENT

ACT Biotech's Telatinib receives orphan drug designation from FDA for treatment of gastric cancer

Insulin pills to manage diabetes are finally moving ahead in clinical trials

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Covidien launches V-Loc 90 knotless wound closure device

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News